Cargando…
Toripalimab in an advanced non-small cell lung cancer patient with poor general condition after multiline treatment: a case report
Several clinical trials have proven that immunotherapy can improve survival and benefit non-small cell lung cancer (NSCLC) patients. In patients who progress after chemotherapy, immune checkpoint inhibitor (ICI) monotherapy can prolong overall survival compared with patients receiving single-agent c...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493187/ https://www.ncbi.nlm.nih.gov/pubmed/34605304 http://dx.doi.org/10.1177/03000605211042988 |